Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel Prize-winning technology faces a basic math problem: It’s not profitable to spend millions of dollars making a drug that may only treat one person.
The solution, according to gene editing pioneer David Liu and his colleagues, is to bring everyone involved together — including patients, hospitals, scientists, drug companies and manufacturers — to make each step of the process simpler, faster and cheaper. Rather than the current bespoke method where each step is tailored and price tags can top $3 million, a ...